{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:06:19Z","timestamp":1793815579665,"version":"4.6.1"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.critrevonc.2025.104712","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T21:58:06Z","timestamp":1743890286000},"page":"104712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Unveiling the Role of JAK2\/STAT3 signaling in chemoresistance of gynecological cancers: From mechanisms to therapeutic implications"],"prefix":"10.1016","volume":"211","author":[{"given":"Tianxiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Xiaohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104712_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/1471-2407-14-317","article-title":"Inhibition of the JAK2\/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden","volume":"14","author":"Abubaker","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.104712_bib2","doi-asserted-by":"crossref","first-page":"86803","DOI":"10.18632\/oncotarget.13466","article-title":"Niclosamide and its analogs are potent inhibitors of Wnt\/\u03b2-catenin, mTOR and STAT3 signaling in ovarian cancer","volume":"7","author":"Arend","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104712_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/CMAR.S457221","article-title":"Deguelin Restores Paclitaxel Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells via Inhibition of the EGFR Signaling Pathway","author":"Bae","year":"2024","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.critrevonc.2025.104712_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2019.11.017","article-title":"JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK\/STAT signalling pathway in ovarian cancer","volume":"126","author":"Bagratuni","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104712_bib5","first-page":"1","article-title":"Sedentary behaviour in relation to ovarian cancer risk: a systematic review and meta-analysis","author":"Biller","year":"2021","journal-title":"Eur. J. Epidemiol."},{"issue":"n\/a","key":"10.1016\/j.critrevonc.2025.104712_bib6","article-title":"Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways","author":"Bischof","year":"2024","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib7","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1002\/cncr.32985","article-title":"Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition","volume":"126","author":"Blessing","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104712_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061451","article-title":"Targeting the JAK\/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy","volume":"9","author":"Bose","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2025.104712_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104712_bib10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.drup.2009.07.001","article-title":"Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib","volume":"12","author":"Broxterman","year":"2009","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.critrevonc.2025.104712_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142677","article-title":"Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer","volume":"131","author":"Burston","year":"2021","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.critrevonc.2025.104712_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052420","article-title":"JAK2-Mediated Phosphorylation of Stress-Induced Phosphoprotein-1 (STIP1) in Human Cells","volume":"23","author":"Chao","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104712_bib13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13273-023-00360-3","article-title":"YTHDC1 inhibits cell proliferation and angiogenesis in cervical cancer by regulating m6A modification of SOCS4 mRNA","volume":"20","author":"Chen","year":"2024","journal-title":"Mol. Cell Toxicol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib14","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1186\/s12967-023-04762-8","article-title":"RUNX1 knockdown induced apoptosis and impaired EMT in high-grade serous ovarian cancer cells","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2025.104712_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108728","article-title":"Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2\/STAT3\/PD-L1 pathway","volume":"227","author":"Chen","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib16","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1158\/0008-5472.CAN-16-1115","article-title":"The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer","volume":"77","author":"Chen","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104712_bib17","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1111\/jcmm.17802","article-title":"Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL-6-STAT3 signalling","volume":"27","author":"Chi","year":"2023","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.critrevonc.2025.104712_bib18","doi-asserted-by":"crossref","first-page":"11890","DOI":"10.3390\/ijms241511890","article-title":"An overview of PARP resistance in ovarian cancer from a molecular and clinical perspective","volume":"24","author":"Cordani","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104712_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005627","article-title":"STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer","volume":"11","author":"Ding","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104712_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/inorganics12120331","article-title":"Platinum\u2013Iron Nanoparticles for Oxygen-Enhanced Sonodynamic Tumor Cell Suppression","volume":"12","author":"Dong","year":"2024","journal-title":"Inorganics"},{"key":"10.1016\/j.critrevonc.2025.104712_bib21","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1038\/s41388-018-0189-0","article-title":"Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3\/Rab proteins","volume":"37","author":"Dorayappan","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2025.104712_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ygyno.2021.08.001","article-title":"Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis","volume":"163","author":"D\u2019Amora","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib23","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1186\/s12885-020-07274-6","article-title":"TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells","volume":"20","author":"Escalona","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.104712_bib24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41419-020-2735-2","article-title":"Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer","volume":"11","author":"Fang","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2025.104712_bib25","article-title":"MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression","volume":"5","author":"Fan","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.critrevonc.2025.104712_bib26","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3892\/ol.2013.1591","article-title":"Corosolic acid enhances the antitumor effects of chemotherapy on epithelial ovarian cancer by inhibiting signal transducer and activator of transcription 3 signaling","volume":"6","author":"Fujiwara","year":"2013","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2025.104712_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2024.2432117","article-title":"LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2\/STAT3 signalling pathway","volume":"25","author":"Gai","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.critrevonc.2025.104712_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10080276","article-title":"Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression","volume":"10","author":"Gao","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104712_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41698-024-00593-y","article-title":"Blocking Oncostatin M receptor abrogates STAT3 mediated integrin signaling and overcomes chemoresistance in ovarian cancer","volume":"8","author":"Geethadevi","year":"2024","journal-title":"Npj Precis Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib30","article-title":"Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer","volume":"32","author":"Geoffroy","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib31","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.2147\/IJN.S248667","article-title":"Nanoparticle BAF312@ CaP-NP overcomes sphingosine-1-phosphate receptor-1-mediated chemoresistance through inhibiting S1PR1\/P-STAT3 axis in ovarian carcinoma","author":"Gong","year":"2020","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.critrevonc.2025.104712_bib32","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/1535-7163.MCT-21-0689","article-title":"Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer","volume":"21","author":"Gopinathan","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.104712_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.367","article-title":"Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429","volume":"8","author":"Guo","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2025.104712_bib34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.62347\/XOPN6908","article-title":"Activation of cGAS confers PARP inhibitor resistance in ovarian cancer via the TBK1-IRF3 axis","volume":"17","author":"Guo","year":"2024","journal-title":"Int J. Clin. Exp. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib35","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.3390\/cells9102297","article-title":"Role of the JAK\/STAT pathway in cervical cancer: its relationship with HPV E6\/E7 oncoproteins","volume":"9","author":"Guti\u00e9rrez-Hoya","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2025.104712_bib36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.21873\/cgp.20291","article-title":"CRY1 regulates Chemoresistance in association with NANOG by inhibiting apoptosis via STAT3 pathway in patients with cervical Cancer","volume":"18","author":"Han","year":"2021","journal-title":"Cancer Genom. Proteom."},{"key":"10.1016\/j.critrevonc.2025.104712_bib37","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.biopha.2017.11.022","article-title":"Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical cancer through suppressing Bcl-2 signaling pathway via inactivating STAT3\/NF-\u03baB","volume":"96","author":"Han","year":"2017","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2025.104712_bib38","doi-asserted-by":"crossref","first-page":"24304","DOI":"10.18632\/oncotarget.24368","article-title":"Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer","volume":"9","author":"Han","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104712_bib39","doi-asserted-by":"crossref","first-page":"10960","DOI":"10.3390\/ijms241310960","article-title":"Potentiation of cisplatin cytotoxicity in resistant ovarian cancer SKOV3\/cisplatin cells by quercetin pre-treatment","volume":"24","author":"Hasan","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104712_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26020799","article-title":"Re-Sensitization of Resistant Ovarian Cancer SKOV3\/CDDP Cells to Cisplatin by Curcumin Pre-Treatment","volume":"26","author":"Hasan","year":"2025","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104712_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1023177","article-title":"The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ejmech.2018.08.037","article-title":"Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis","volume":"157","author":"Huang","year":"2018","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.critrevonc.2025.104712_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.595789","article-title":"Histological characteristics and early-stage diagnosis are associated with better survival in young patients with epithelial ovarian cancer: a retrospective analysis based on surveillance epidemiology and end results database","volume":"10","author":"Huang","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib44","article-title":"SiRNA interfering STAT3 enhances DDP sensitivity in cervical cancer cells","volume":"22","author":"Huang","year":"2018","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.critrevonc.2025.104712_bib45","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.7150\/thno.26627","article-title":"Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling","volume":"8","author":"Huang","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2025.104712_bib46","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.7150\/jca.14519","article-title":"Proteasome inhibitor YSY01A enhances cisplatin cytotoxicity in cisplatin-resistant human ovarian cancer cells","volume":"7","author":"Huang","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104712_bib47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104712_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104712_bib49","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2025.104712_bib50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41419-018-1200-y","article-title":"Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3","volume":"10","author":"Hu","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2025.104712_bib51","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3389\/fphar.2018.00530","article-title":"Anticancer activity and mechanism of xanthohumol: a prenylated flavonoid from hops (Humulus lupulus L.)","volume":"9","author":"Jiang","year":"2018","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.104712_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1353056","article-title":"Natural products\u2019 antiangiogenic roles in gynecological cancer","volume":"15","author":"Jia","year":"2024","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.104712_bib53","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3892\/or.2017.5886","article-title":"Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail\u2011glycolysis pathways","volume":"38","author":"Jia","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2025.104712_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010217","article-title":"Role of JAK\/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial\u2013Mesenchymal Transition","volume":"9","author":"Jin","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2025.104712_bib55","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.canlet.2013.08.022","article-title":"Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer","volume":"341","author":"Ji","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2025.104712_bib56","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1158\/0008-5472.CAN-16-0980","article-title":"Ovarian cancer chemoresistance relies on the stem cell reprogramming factor PBX1","volume":"76","author":"Jung","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104712_bib57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12032-023-01957-3","article-title":"Epidemiological trends and risk factors of gynecological cancers: an update","volume":"40","author":"Keyvani","year":"2023","journal-title":"Med Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11123155","article-title":"Tephrosin Suppresses the Chemoresistance of Paclitaxel-Resistant Ovarian Cancer via Inhibition of FGFR1 Signaling Pathway","volume":"11","author":"Kim","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2025.104712_bib59","article-title":"CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis","volume":"24","author":"Kim","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104712_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.223","article-title":"Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2","volume":"4","author":"Koo","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2025.104712_bib61","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.omto.2022.04.006","article-title":"Inhibition of MEK-ERK pathway enhances oncolytic vaccinia virus replication in doxorubicin-resistant ovarian cancer","volume":"25","author":"Lee","year":"2022","journal-title":"Mol. Ther. - Oncolytics"},{"key":"10.1016\/j.critrevonc.2025.104712_bib62","doi-asserted-by":"crossref","first-page":"837","DOI":"10.7150\/jca.35011","article-title":"STAT3 signaling in ovarian cancer: a potential therapeutic target","volume":"11","author":"Liang","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104712_bib63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41389-019-0165-8","article-title":"The crosstalk between STAT3 and p53\/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug\/MAPK\/PI3K\/AKT-mediated regulation of EMT and autophagy","volume":"8","author":"Liang","year":"2019","journal-title":"Oncogenesis"},{"key":"10.1016\/j.critrevonc.2025.104712_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29010274","article-title":"Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells","volume":"29","author":"Lim","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.critrevonc.2025.104712_bib65","article-title":"A clinical prognostic model related to T cells based on machine learning for predicting the prognosis and immune response of ovarian cancer","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.critrevonc.2025.104712_bib66","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s10495-016-1334-2","article-title":"Quercetin induces protective autophagy and apoptosis through ER stress via the p-STAT3\/Bcl-2 axis in ovarian cancer","volume":"22","author":"Liu","year":"2017","journal-title":"Apoptosis"},{"key":"10.1016\/j.critrevonc.2025.104712_bib67","doi-asserted-by":"crossref","first-page":"9671","DOI":"10.1007\/s13277-016-4848-x","article-title":"NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer","volume":"37","author":"Liu","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib68","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.3892\/mmr.2015.3716","article-title":"Quinolone-indolone conjugate induces apoptosis by inhibiting the EGFR-STAT3-HK2 pathway in human cancer cells","volume":"12","author":"Liu","year":"2015","journal-title":"Mol. Med Rep."},{"key":"10.1016\/j.critrevonc.2025.104712_bib69","article-title":"PBRM1 presents a potential ctDNA marker to monitor response to neoadjuvant chemotherapy in cervical cancer","volume":"27","author":"Li","year":"2024","journal-title":"IScience"},{"key":"10.1016\/j.critrevonc.2025.104712_bib70","first-page":"2124","article-title":"Exosomal transfer of miR-429 confers chemoresistance in epithelial ovarian cancer","volume":"11","author":"Li","year":"2021","journal-title":"Am. J. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104712_bib71","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41419-021-03635-6","article-title":"SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance","volume":"12","author":"Li","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2025.104712_bib72","first-page":"249","article-title":"ERp57\u2011small interfering RNA silencing can enhance the sensitivity of drug\u2011resistant human ovarian cancer cells to paclitaxel","volume":"54","author":"Li","year":"2019","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.724104","article-title":"PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer","volume":"11","author":"Martincuks","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib74","doi-asserted-by":"crossref","first-page":"216","DOI":"10.18632\/oncoscience.26","article-title":"Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor","volume":"1","author":"McCann","year":"2014","journal-title":"Oncoscience"},{"key":"10.1016\/j.critrevonc.2025.104712_bib75","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ijgo.13871","article-title":"Progress in the pathological arena of gynecological cancers","volume":"155","author":"McCluggage","year":"2021","journal-title":"Int J. Gynecol. Obstet."},{"key":"10.1016\/j.critrevonc.2025.104712_bib76","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2147\/JIR.S353489","article-title":"Role of JAK2\/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review","volume":"15","author":"Mengie Ayele","year":"2022","journal-title":"J. Inflamm. Res"},{"key":"10.1016\/j.critrevonc.2025.104712_bib77","doi-asserted-by":"crossref","first-page":"22","DOI":"10.25259\/Cytojournal_17_2024","article-title":"Mitochondrial protein isoleucyl-tRNA synthetase 2 in tumor cells as a potential therapeutic target for cervical cancer","volume":"21","author":"Meng","year":"2024","journal-title":"Cytojournal"},{"key":"10.1016\/j.critrevonc.2025.104712_bib78","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41419-020-2327-1","article-title":"ID1 confers cancer cell chemoresistance through STAT3\/ATF6-mediated induction of autophagy","volume":"11","author":"Meng","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2025.104712_bib79","doi-asserted-by":"crossref","DOI":"10.25259\/Cytojournal_8_2021","article-title":"Prevalence of human papillomavirus infection in abnormal pap smears","volume":"20","author":"Mishra","year":"2023","journal-title":"Cytojournal"},{"key":"10.1016\/j.critrevonc.2025.104712_bib80","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/s41416-020-0922-7","article-title":"CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma","volume":"123","author":"Mo","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104712_bib81","doi-asserted-by":"crossref","first-page":"27220","DOI":"10.18632\/oncotarget.25513","article-title":"Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance","volume":"9","author":"Le Naour","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104712_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119513","article-title":"Metal organic framework coated MnO2 nanosheets delivering doxorubicin and self-activated DNAzyme for chemo-gene combinatorial treatment of cancer","volume":"585","author":"Nie","year":"2020","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.critrevonc.2025.104712_bib83","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13046-021-02088-1","article-title":"ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer","volume":"40","author":"Nie","year":"2021","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104712_bib84","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neo.2018.12.005","article-title":"MicroRNA-503-5p Inhibits the CD97-Mediated JAK2\/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells","volume":"21","author":"Park","year":"2019","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2025.104712_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/cells10092218","article-title":"A Novel Monoclonal Antibody Targeting Cancer-Specific Plectin Has Potent Antitumor Activity in Ovarian Cancer","volume":"10","author":"Perez","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2025.104712_bib86","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12935-023-03202-3","article-title":"Interplay of miRNAs and lncRNAs in STAT3 signaling pathway in colorectal cancer progression","volume":"24","author":"Rahbar","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.critrevonc.2025.104712_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.821344","article-title":"JAK\/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies","volume":"13","author":"Rah","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2025.104712_bib88","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/ph17081083","article-title":"Design, synthesis, and evaluation of Oleyl-WRH peptides for siRNA delivery","volume":"17","author":"Rai","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.critrevonc.2025.104712_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082361","article-title":"Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer","volume":"15","author":"Raspaglio","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104712_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041000","article-title":"Epigallocatechin-3-Gallate Prevents the Acquisition of a Cancer Stem Cell Phenotype in Ovarian Cancer Tumorspheres through the Inhibition of Src\/JAK\/STAT3 Signaling","volume":"11","author":"Rodriguez Torres","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2025.104712_bib91","first-page":"77","article-title":"Chapter 4 - Mechanisms of chemoresistance and approaches to overcome its impact in gynecologic cancers","volume":"17","author":"Sabnis","year":"2021"},{"key":"10.1016\/j.critrevonc.2025.104712_bib92","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib93","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bbrc.2022.05.091","article-title":"Inhibition of STAT3 reverses Taxol-resistance in ovarian cancer by down-regulating G6PD expression in vitro","volume":"617","author":"Sheng","year":"2022","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.critrevonc.2025.104712_bib94","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1590\/1414-431X20133003","article-title":"Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer","volume":"46","author":"Sheng","year":"2013","journal-title":"Braz. J. Med Biol. Res"},{"key":"10.1016\/j.critrevonc.2025.104712_bib95","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.canlet.2017.09.048","article-title":"Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment","volume":"411","author":"Shu","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2025.104712_bib96","first-page":"3351","article-title":"Oncostatin M treatment increases the responsiveness toward cisplatin-based chemoradiotherapy in cervical cancer cells in a STAT3-dependent manner","volume":"16","author":"Stroeder","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2025.104712_bib97","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1111\/cas.15780","article-title":"LRRC75A-AS1 delivered by M2 macrophage exosomes promotes cervical cancer progression via enhancing SIX1 expression","volume":"114","author":"Sui","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2025.104712_bib98","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/cas.16014","article-title":"Extracellular vesicle-encapsulated microRNA-296-3p from cancer-associated fibroblasts promotes ovarian cancer development through regulation of the PTEN\/AKT and SOCS6\/STAT3 pathways","volume":"115","author":"Sun","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2025.104712_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113993","article-title":"Disorders of cancer metabolism: The therapeutic potential of cannabinoids","volume":"157","author":"Sun","year":"2023","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2025.104712_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188525","article-title":"Autophagy signals orchestrate chemoresistance of gynecological cancers","volume":"1875","author":"Tam","year":"2021","journal-title":"Biochim Biophys. Acta - Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104712_bib101","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71153-0","article-title":"Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling","volume":"10","author":"Tan","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104712_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194675","article-title":"Inhibition of Tumor Microenvironment Cytokine Signaling Sensitizes Ovarian Cancer Cells to Antiestrogen Therapy","volume":"14","author":"Tan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104712_bib103","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41419-022-04510-8","article-title":"Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion","volume":"13","author":"Tian","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2025.104712_bib104","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.7150\/jca.58979","article-title":"LncRNA-H19 regulates chemoresistance to carboplatin in epithelial ovarian cancer through microRNA-29b-3p and STAT3","volume":"12","author":"Tian","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104712_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/srep29588","article-title":"Onionin A inhibits ovarian cancer progression by suppressing cancer cell proliferation and the protumour function of macrophages","volume":"6","author":"Tsuboki","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104712_bib106","first-page":"1333","article-title":"Erythropoietin promotes expression of survivin via STAT3 activation and reduces sensitivity to cisplatin in cervical cancer cells","volume":"41","author":"V\u00e1zquez\u2011Mellado","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2025.104712_bib107","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.tranon.2018.07.010","article-title":"Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies","volume":"11","author":"Veskim\u00e4e","year":"2018","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib108","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1039\/D4NA00227J","article-title":"Nanoparticle co-delivery of carboplatin and PF543 restores platinum sensitivity in ovarian cancer models through inhibiting platinum-induced pro-survival pathway activation","volume":"6","author":"Wang","year":"2024","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.critrevonc.2025.104712_bib109","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","article-title":"Drug resistance in ovarian cancer: from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104712_bib110","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/1453739","article-title":"Suppression of GCH1 Sensitizes Ovarian Cancer and Breast Cancer to PARP Inhibitor","volume":"2023","author":"Wang","year":"2023","journal-title":"J. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib111","first-page":"2081","article-title":"CAFs enhance paclitaxel resistance by inducing EMT through the IL\u20116\/JAK2\/STAT3 pathway","volume":"39","author":"Wang","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2025.104712_bib112","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","article-title":"How Taxol\/paclitaxel kills cancer cells","volume":"25","author":"Weaver","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.critrevonc.2025.104712_bib113","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1021\/acs.jnatprod.1c01166","article-title":"Discovery of natural ursane-type SENP1 inhibitors and the platinum resistance reversal activity against human ovarian cancer cells: a structure\u2013activity relationship study","volume":"85","author":"Wei","year":"2022","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.critrevonc.2025.104712_bib114","doi-asserted-by":"crossref","first-page":"22716","DOI":"10.18632\/oncotarget.15187","article-title":"Therapeutically blocking interleukin-11 receptor-\u03b1 enhances doxorubicin cytotoxicity in high grade type I endometrioid tumours","volume":"8","author":"Winship","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104712_bib115","doi-asserted-by":"crossref","first-page":"371","DOI":"10.34133\/research.0371","article-title":"Progesterone enhances Niraparib Efficacy in Ovarian Cancer by promoting palmitoleic-acid-mediated ferroptosis","volume":"7","author":"Wu","year":"2024","journal-title":"Research"},{"key":"10.1016\/j.critrevonc.2025.104712_bib116","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20208885","article-title":"Treatment with \u03b2-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-\u03baB pathway","volume":"53","author":"Xiaomeng","year":"2020","journal-title":"Braz. J. Med Biol. Res"},{"key":"10.1016\/j.critrevonc.2025.104712_bib117","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ygyno.2022.01.014","article-title":"Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation","volume":"164","author":"Xia","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib118","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2025.104712_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173817","article-title":"IL-6 promotes nuclear translocation of HIF-1\u03b1 to aggravate chemoresistance of ovarian cancer cells","volume":"894","author":"Xu","year":"2021","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.critrevonc.2025.104712_bib120","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0000000000000550","article-title":"Inhibition of JAK2 reverses paclitaxel resistance in human ovarian cancer cells","volume":"25","author":"Xu","year":"2015","journal-title":"Int J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104712_bib121","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.3390\/cancers12092459","article-title":"STAT3, the challenge for chemotherapeutic and radiotherapeutic efficacy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104712_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116040","article-title":"WP1066, a small molecule inhibitor of STAT3, chemosensitizes paclitaxel-resistant ovarian cancer cells to paclitaxel by simultaneously inhibiting the activity of STAT3 and the interaction of STAT3 with Stathmin","volume":"221","author":"Yang","year":"2024","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.critrevonc.2025.104712_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106357","article-title":"Inhibiting STAT3 signaling pathway by natural products for cancer prevention and therapy: In vitro and in vivo activity and mechanisms of action","volume":"182","author":"Yang","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.critrevonc.2025.104712_bib124","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.bbrc.2016.01.131","article-title":"Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling","volume":"470","author":"Yan","year":"2016","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.critrevonc.2025.104712_bib125","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3892\/or.2015.3769","article-title":"Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1\/STAT3 in the cervical carcinoma cell line C33A","volume":"33","author":"Yan","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2025.104712_bib126","doi-asserted-by":"crossref","first-page":"9605","DOI":"10.1002\/jcp.27647","article-title":"Growth arrest-specific 5 attenuates cisplatin-induced apoptosis in cervical cancer by regulating STAT3 signaling via miR-21","volume":"234","author":"Yao","year":"2019","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib127","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12935-016-0379-1","article-title":"Overexpression of trefoil factor 3 (TFF3) contributes to the malignant progression in cervical cancer cells","volume":"17","author":"Yuan","year":"2017","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.critrevonc.2025.104712_bib128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.critrevonc.2025.104712_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105633","article-title":"Design, synthesis and biological evaluation of antitumor platinum(II) agents conjugated with non-steroidal anti-inflammatory drug species","volume":"120","author":"Zang","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.critrevonc.2025.104712_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2022.122000","article-title":"Serum Raman spectroscopy combined with convolutional neural network for rapid diagnosis of HER2-positive and triple-negative breast cancer","volume":"286","author":"Zeng","year":"2023","journal-title":"Spectrochim. Acta Part A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.critrevonc.2025.104712_bib131","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3892\/or.2020.7667","article-title":"A small molecule STAT3 inhibitor, LLL12, enhances cisplatin\u2011 and paclitaxel\u2011mediated inhibition of cell growth and migration in human ovarian cancer cells","volume":"44","author":"Zhang","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2025.104712_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109770","article-title":"STAT3 as a therapeutic target in the metformin-related treatment","volume":"116","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib133","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40164-025-00620-z","article-title":"Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib134","doi-asserted-by":"crossref","first-page":"37459","DOI":"10.1021\/acsomega.4c04573","article-title":"Strategies, Challenges, and Prospects of Nanoparticles in Gynecological Malignancies","volume":"9","author":"Zhang","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.critrevonc.2025.104712_bib135","doi-asserted-by":"crossref","first-page":"70130","DOI":"10.18632\/oncotarget.19593","article-title":"Physapubescin B inhibits tumorgenesis and circumvents taxol resistance of ovarian cancer cells through STAT3 signaling","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104712_bib136","article-title":"Immunoadjuvant-functionalized metal-organic frameworks: synthesis and applications in tumor immune modulation","author":"Zhao","year":"2025","journal-title":"Chem. Commun."},{"key":"10.1016\/j.critrevonc.2025.104712_bib137","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40170-024-00370-2","article-title":"Silencing of STEAP3 suppresses cervical cancer cell proliferation and migration via JAK\/STAT3 signaling pathway","volume":"12","author":"Zhao","year":"2024","journal-title":"Cancer Metab."},{"key":"10.1016\/j.critrevonc.2025.104712_bib138","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/jnci\/djae164","article-title":"Ovarian cancer risk factors in relation to family history","volume":"116","author":"Zheng","year":"2024","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2025.104712_bib139","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3892\/or.2021.8020","article-title":"Triptolide inhibits JAK2\/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatin\u2011resistant SKOV3\/DDP ovarian cancer cells","volume":"45","author":"Zhong","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2025.104712_bib140","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1465987","article-title":"Nanoparticles in gynecologic cancers: a bibliometric and visualization analysis","volume":"14","author":"Zhou","year":"2025","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.119126","article-title":"Chrysotoxine regulates ferroptosis and the PI3K\/AKT\/mTOR pathway to prevent cervical cancer","volume":"338","author":"Zhou","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib142","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41598-024-52413-9","article-title":"Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer","volume":"14","author":"Zhou","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104712_bib143","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3892\/ijo.2016.3442","article-title":"Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K\/Akt signaling pathways","volume":"48","author":"Zhou","year":"2016","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104712_bib144","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1038\/s41388-018-0238-8","article-title":"Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance","volume":"37","author":"Zhou","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2025.104712_bib145","doi-asserted-by":"crossref","first-page":"39154","DOI":"10.18632\/oncotarget.16610","article-title":"IL-6R\/STAT3\/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104712_bib146","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in Cancer Immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T20:28:38Z","timestamp":1749500918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":146,"alternative-id":["S1040842825001003"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104712","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unveiling the Role of JAK2\/STAT3 signaling in chemoresistance of gynecological cancers: From mechanisms to therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104712"}}